Therapy News and Research

RSS

Gut microbial imbalance linked to chronic sickle cell disease pain

A research collaboration involving scientists and students at The University of Texas at Dallas has found a clear connection between chronic sickle cell disease pain and the bacteria present in the gastrointestinal tract.

22 Sep 2025

Inflammatory cells drive lung underdevelopment in congenital diaphragmatic hernia

Congenital diaphragmatic hernia (CDH) is a dangerous malformation of the lungs and diaphragm that causes almost a third of affected babies to die from underdeveloped lungs. So far, there have been no concrete options for treating this malformation with medication.

22 Sep 2025

New molecular signatures map the stepwise development of gastric cancer

Gastric cancer often develops through a gradual sequence of changes, beginning with superficial gastritis and advancing through chronic atrophic gastritis, intestinal metaplasia, and precancerous lesions before culminating in malignancy.

22 Sep 2025

Psychological distress after a heart attack emerges as a critical risk factor for heart health

Many people experience one or more types of psychological distress, including depression, anxiety, psychosocial stress or post-traumatic stress disorder (PTSD), after a heart attack, which can affect their physical recovery and long-term heart health, according to a new American Heart Association scientific statement, published today in the American Heart Association's flagship, peer-reviewed journal Circulation.

22 Sep 2025

States are cutting Medicaid provider payments long before Trump cuts hit

Every day for nearly 18 years, Alessandra Fabrello has been a medical caregiver for her son, on top of being his mom.

22 Sep 2025

PRMT5 inhibition induces ferroptosis and enhances immunotherapy efficacy in renal cell carcinoma

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.

22 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

Coffee protects the liver by blocking inflammation and scarring, review finds

A new review in Biochemical Pharmacology synthesizes decades of research showing consistent links between regular coffee consumption and reduced risk of liver disease, including cirrhosis and liver cancer. Coffee’s bioactive compounds act on antioxidant, anti-inflammatory, antifibrotic, and metabolic pathways to slow liver damage progression.

21 Sep 2025

Study in Florida finds racial disparities in heart attack treatment

While acute myocardial infarction - commonly referred to as a heart attack - remains a leading cause of death in the United States, deaths have decreased significantly over the past two decades in part due to improved treatment methods, according to Charleen Hsuan, associate professor of health policy and administration at Penn State.

19 Sep 2025

COST Actions drive innovation in cancer research across Europe

Cancer is a major challenge in the modern world, affecting millions of people across Europe. The prevalence of this disease requires the development of innovative and complementary treatment approaches.

19 Sep 2025

AGA releases new clinical guideline for diagnosing and managing gastroparesis

The American Gastroenterological Association (AGA) has released a new clinical guideline with 12 conditional recommendations for diagnosing and managing gastroparesis, a serious and often debilitating disease.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale.

19 Sep 2025

New findings support low-dose ATG to delay progression of type 1 diabetes

New research presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published simultaneously in The Lancet shows that a much lower dose than previously thought of the old immunomodulatory drug anti-thymocyte globulin (ATG) is safe and effective in preventing progression of type 1 diabetes (T1D) in young people.

19 Sep 2025

New research aims to use eyedrops to lower lifetime risk of nearsightedness complications

For the first time, researchers are leading a national study to see if the onset of nearsightedness can be delayed – and consequently reduced in magnitude over a lifetime – with the use of eyedrops in young children.

19 Sep 2025

Genomic testing speeds patient accrual in high-risk prostate cancer trial

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial's anticipated accrual completion date.

19 Sep 2025

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Study reveals early nicotinamide use reduces risk of aggressive skin cancers

A large U.S. Department of Veterans Affairs cohort study found that Nicotinamide use was associated with a 14% lower risk of new keratinocyte skin cancers, driven by a 22% reduction in cSCC and no reduction in BCC. The strongest benefit (56% lower risk) appeared when nicotinamide was started after a patient’s first skin cancer, with diminishing returns after multiple cancers.

18 Sep 2025